Assessing serotonin receptor mRNA editing frequency by a novel ultra high-throughput sequencing method

Atheer I. Abbas1, Daniel J. Urban2, Niels H. Jensen2, Martilias S. Farrell2, Wesley K. Kroeze2, Piotr Mieczkowski3, Zefeng Wang2 and Bryan L. Roth2,4,5,6,∗

1Department of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, 2Department of Pharmacology, 3Department of Genetics, 4Department of Psychiatry and Lineberger Cancer Center, School of Medicine, 5Department of Medicinal Chemistry, School of Pharmacy and 6National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA

Received August 5, 2009; Revised February 3, 2010; Accepted February 4, 2010

ABSTRACT

RNA editing is a post-transcriptional modification of pre-mRNA that results in increased diversity in transcriptomes and proteomes. It occurs in a wide variety of eukaryotic organisms and in some viruses. One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation. This phenomenon has been observed in numerous transcripts, including the mammalian 5-HT2C receptor, which can be edited at five distinct sites. Methods used to date to quantify 5-HT2C receptor editing are labor-intensive, expensive and provide limited information regarding the relative abundance of 5-HT2C receptor editing variants. Here, we present a novel, ultra high-throughput method to quantify 5-HT2C receptor editing, compare it to a more conventional method, and use it to assess the effect of a range of genetic and pharmacologic manipulations on 5-HT2C editing. We conclude that this new method is powerful and economical, and we provide evidence that alterations in 5-HT2C editing appear to be a result of regional changes in brain activity, rather than a mechanism to normalize 5-HT2C signaling.

INTRODUCTION

The post-transcriptional modification of RNA, or RNA editing, was first reported in trypanosome mitochondria (1). Deamination of adenosine to inosine, the most common type of RNA editing in higher eukaryotes (2), was first demonstrated in mammals at murine glutamate receptor subunit transcripts (3) and has been reported in organisms ranging from fruit flies to rodents and humans, and a number of instances have been reported in viruses (4). A family of enzymes referred to as Adenosine Deaminases that Act on RNA (ADAR) performs the deaminations, which underlie this type of RNA editing (2). It has been shown that the genetic deletion of all ADAR activity in Drosophila severely impairs central nervous system (CNS) function and integrity (5). A-to-I editing has been shown to be critical for normal embryogenesis in mammals, since genetic deletion of ADAR1 in mice is embryonically lethal (6). Genetic deletion of ADAR2 in mice, on the other hand, increases seizure susceptibility and decreases post-natal survival (7). The inosine content of transcripts isolated from different tissues suggests that the known edited transcripts only account for a small fraction of the editing that is likely to take place, that RNA editing takes place predominantly in non-coding regions of RNA transcripts containing inverted repetitive elements of the Alu and L1 subclass, and that RNA editing is most common in the brain (8–13).

The 5-hydroxytryptamine-2C (5-HT2C; HTR2C) serotonin receptor is the only G protein-coupled receptor (GPCR), whose transcripts have been shown to undergo RNA editing. RNA editing of 5-HT2C transcripts takes place at one or more of five closely spaced adenosines in a region that codes for a portion of the second intracellular loop of the receptor (14,15). ADAR1 has been shown to be primarily responsible for editing the two 5’ sites, while ADAR2 edits the two 3’ sites (16). RNA editing has been shown to reduce the efficiency of
5-HT$_{2C}$ receptor-G protein-coupling (17,14). Recent in vivo studies suggest that the altered signaling properties of 5-HT$_{2C}$ isoforms that result from RNA editing can lead to physiological consequences, as mutant mice expressing only the fully edited VGV isoform are characterized by significant abnormalities in receptor expression, feeding, and metabolism (18).

5-HT$_{2C}$ RNA editing abnormalities have been reported in the brains of suicide victims with a history of major depression, whereas treatment with the antidepressant drug fluoxetine induces changes in the opposite direction (15). Other studies have suggested changes in editing after treatment with the antidepressant in the brains of suicide victims with a history of major depression, whereas treatment with the antidepressant in the brains of suicide victims with a history of major depression. 

The observed changes, given the known activities and specificities of ADAR1 and ADAR2, is the tent and difficult to replicate (15,22). Furthermore, it is inadequate for quantifying the levels of rare transcripts. Other methods include primer extension assays (25) and pyrosequencing (26), which are quantitative and provide information about editing frequencies at each site, but give insufficient or no information regarding the frequencies of the different transcripts/isoforms. We have adapted a newly developed ultra high-throughput sequencing (HTS) technology, the Illumina Genome Analyzer II, to quantify 5-HT$_{2C}$ pre-mRNA editing. This approach is several orders of magnitude less expensive on a per transcript basis, and provides more comprehensive and quantitative information regarding RNA editing events. We compare our HTS-based method to the most commonly used individual sequencing method and assess the effect of a range of genetic manipulations and pharmacologic treatments on 5-HT$_{2C}$ editing.

**MATERIALS AND METHODS**

**Mice**

A detailed description of how the Pet-1 mice were generated has been reported previously (27). C57BL/6 mice were purchased from Jackson Laboratories. C57BL/6 mice were injected with either saline or drug daily for 10, 14 or 28 days and sacrificed on the last day of injections. Different brain regions were then microdissected and frozen at $-80^\circ$C until use. Treatment dose and length were based on literature reports of drug regimens that resulted in measurable effects at the biochemical and/or behavioral level (see the relevant ‘Results’ section for the individual citations). All experiments were approved by the Institutional Animal Care and Use Committee at Case Western Reserve University or the University of North Carolina, Chapel Hill. Mice were housed under standard conditions—12 h light/dark cycle and food and water ad libitum.

**Generation of cDNA from RNA**

Trizol (Invitrogen) was used to extract RNA from microdissected hippocampal tissue. Ten µg of RNA was treated with DNase (DNA-free, Ambion), and 2 µg of the DNase-treated RNA was added to a reverse transcription reaction which was performed using the Superscript$^\text{TM}$ III RNase H Reverse Transcriptase kit (Invitrogen) with Oligo-(dT)$_{12-18}$ primers (Invitrogen). cDNA was used as template to generate a double-stranded DNA fragment by PCR for both the low-throughput sequencing (LTS) and high-throughput sequencing (HTS) experiments.

**LTS**

A PCR fragment (containing the edited site) that was 327 bp in length was generated for each of three Pet-1 wild-type and three Pet-1 knockout animals (Forward primer: 5’ AAA GGATCC TGT GCT ATT TTC AAC TGC GTC CAT CAT G 3’; Reverse primer: 5’ AAA GAA TTC CGG CGT AGG ACG TAG ATC GTTAA G 3’) (24). The PCR DNA concentrations were determined, and the DNA from the three animals of each genotype was mixed in equal amounts and inserted into the BamHI/ EcoRI sites of pcDNA3 (Rapid DNA ligation kit, Roche). The ligation product was transformed into bacteria and plated; each clone represents an individual transcript, and the clones were assumed to be evenly distributed in origin between the three animals used for each ligation since equal amounts of DNA were used from each in the ligation reaction. Clones were miniprepped using the Wizard Plus SV Miniprep kit (Promega), and they were sequenced by Sanger sequencing to assess 5-HT$_{2C}$ RNA editing. Seventy-eight wild-type transcripts and 88 knockout transcripts were sequenced.

**Ultra HTS**

5-HT$_{2C}$ editing in Pet-1 mice. One microliter of cDNA (of 20 µl) was used as template for a 50 µl PCR reaction (conditions: 1 cycle—95°C, 2 min; 30 cycles—95°C 30 s, 52°C 30 s, 72°C 1 min; 1 cycle—72°C 10 min) to amplify a fragment (lowercase letters for the portions of the primers complementary to 5-HT$_{2C}$ sequence) containing the edited region of interest using Pfu turbo polymerase (Stratagene). The primers used also contained adapter sequences (uppercase letters in bold) necessary for cluster generation:

- Forward primer: AATGATACGGGCGACCACGAGAT CTACACTgccgacgaccggatat;
- Reverse primer: CAAGCAGAGACCGCATACGAGAT gcacgaaggaccggatatagc

PCR fragments (283 bp in length) were gel purified using the QIAquick gel extraction kit, and 1 µl was used
as template for another round of PCR, though a second round of PCR is typically unnecessary since <100 ng of DNA is needed from each experiment using fragments of this size.

**5-HT$_{2C}$ editing in chronic saline and drug-treated C57BL/6 mice.** Performed as described above, except the round one PCR reaction was 20 μl. Additionally, the forward primer contained a sequence corresponding to a sequencing primer optimized by Illumina for use with the Genome Analyzer II (non-bolded uppercase letters), as well as a sample identification tag, which was a random nucleotide sequence 5–10 nucleotides in length (underlined uppercase letters, with ‘AAAAA’ being the tag for sample one and the other 25 tags as follows: ATCAT, GGGGG, TTTTT, AAGGT, GGTAT, AATTG, AGTGA, TTGGA, TFAA G, GTGTA, ATATG, ATCAT ATCAT, AAAAA AAA AA, GGGGG GGGGG, TTTTT TTTTT, AAGGT AA GGT, GGTAT GGTAT, AATTG AATTG, AGTGA A GTGA, TTGGA TTGGA, TAAAG TAAAG, GTGTA G TGTGTA, ATATG ATATG, AAAAA GGGGG, GGGGG AAAAA). As before, the bolded, italic portions of the primers represent adapter sequence, and the lower case portions represent sequence complementary to 5-HT$_{2C}$ pre-mRNA sequence. Each sample used a different forward primer (26 different forward primers total) containing a different identification tag, with the rest of the primer being identical. All reactions used the same reverse primer.

Forward primer: AATGATACGGCGACCACCGAGATCTACACCTACCACTCTTTCCCTACACGACGCTCTTCCGATCTAAA
Reverse primer: CAAGCAGAAGACGGCATACGAGAT

One microliter of PCR reaction one was used as template for another round of PCR, the volume of these reactions being 50 μl each, and the 257-bp fragment from this second round of PCR was gel purified using the MinElute PCR Purification kit (QiaGen). A portion of the gel-purified PCR DNA from each sample was used for gel quantification, and 24–26 samples were mixed in equal parts for HTS.

Gel purified PCR DNA was diluted to a concentration of 15 nM. Two microliters was used for denaturation (total volume 20 μl). 4 μl of the denaturation mixture was diluted in 996 μl of hybridization solution. The hybridization mixture (final DNA concentration about 6 pM) was loaded into the Cluster Station for cluster generation. Primer hybridization was performed on the Cluster Station using 6.6 μl of 500 nM sequencing primer (PET-1 experiment primer sequence: gcgccatatcgctggaccggtat; multiplexed experiment primer sequence: tcacagg) diluted in 1313 μl of hybridization buffer. Cluster generation was performed for 36 cycles (Pet-1 experiment) or 76 cycles (fluoxetine experiment), followed by base-by-base sequencing initiated by the sequencing primer on the Genome Analyzer II. The Genome Analyzer II uses two different lasers to excite the dye attached to each nucleotide. Since the emission spectra of these four dyes overlap, the four images thus obtained are not independent. As in Sanger sequencing, the frequency cross-talk is deconvolved using a frequency cross-talk matrix. Therefore, the cross-talk matrix calculation requires control lanes for samples with skewed base compositions. Thus, a control human genomic DNA sample was run in parallel on the same flow-cell concurrently with 5-HT$_{2C}$ editing samples. Any non-skewed DNA library can be used for this purpose. For the Pet-1 experiment, sequences that passed all three of our quality filters were sorted and counted using Textpad. MySQL 4.0, an open source and multi-platform relational database management system, was used to sort and count transcript reads that passed the first filter, which permitted comparison of ‘false’ transcript counts to theoretically real transcript counts. For the multiplexed experiment, sequences were analyzed using a Perl 5 script (available at http://pdp-temp.pha-med.unc.edu/Download/code.php) written by us to filter the data through three quality filters and sort the data which passed the filters. Further data analysis was performed in Microsoft Excel and Graphpad Prism 5.0. All statistical analyses were performed in Graphpad Prism 5.0. N = 3 littermate pairs for the samples used to measure hippocampal 5-HT$_{2C}$ RNA editing in Pet-1 wildtype and knockout mice, whereas N = 4 for the multiplexed experiment. For the purposes of making statistical comparisons, all the reads generated from one animal in the HTS studies were together treated as one experiment (N = 3–4 for each genotype). For the LTS analysis, each read was treated as an experiment (N = 78 for WT, N = 88 for KO).

**RESULTS**

**Processing transcript reads obtained by ultra HTS**

In order to explore the potential of ultra HTS methods for assessing 5-HT$_{2C}$ transcript editing frequencies, we measured RNA editing in hippocampi from Pet-1 wild-type and knockout mice. The hippocampus was chosen because it is the region with the highest expression of neuronal 5-HT$_{2C}$ receptor mRNA (28). Pet-1 is an ETS domain transcription factor that is necessary for the normal development of serotonergic neurons (27), and Pet-1 knockout mice have very low levels of brain serotonin. We also compared two methods for measuring RNA editing and transcript/isofrom frequencies: sequencing individual transcripts by Sanger sequencing versus ultra HTS using reversible terminator chemistry (29,30) with the Illumina Genome Analyzer II platform. The 5-HT$_{2C}$ receptor is A-to-I edited at varying frequencies at one or more of five sites: A, B, C, D and E (Figure 1A). Adenosines deaminated to inosine are read as guanosines when 5-HT$_{2C}$ RNA is reverse-transcribed, PCR-amplified and sequenced. Since the Genome Analyzer II-based ultra HTS read length is 36 bp, the sequencing primer was designed such that it provided reads beginning at the −5 position relative to the first edited site (Table 1). We analyzed three samples from
the aforementioned 22 sites were removed from the pool of sequences. All reads containing errors in any of the eight non-edited sites within the region of interest spanning the A to D sites and/or contained a cytosine or a thymine at one of the edited sites (213,997 sequences). Sequences that failed these last two filters were binned by read and the number of reads in each bin was counted. Interestingly, some of these ‘false transcripts’ occurred at higher frequencies than a number of the rarer transcripts that passed all the filters. Notably, the same false transcripts occurred at high frequency in all the samples examined, and they typically differed from one of the most common transcripts by one base, suggesting that they resulted from misreads of common transcripts. The remaining sequences that passed all three ‘quality filters’ were sorted into 32 bins, one for each theoretically possible transcript (Table 1), and the number of sequence reads in each of these bins was then counted.

Calculating transcript frequency thresholds

The recurrence of the same false transcripts in each sample, some at frequencies higher than theoretically possible transcripts, suggested the possibility that the reads of some of the rarer transcripts may have arisen largely due to A-to-G or G-to-A misreads of more common transcripts. Since it was impossible to determine a priori whether or not this was the case, we first undertook a detailed analysis of the error rates at the first three adenines and guanines in non-edited region 2 (Figure 1B). Noting that adenines and guanines were most commonly misread as cytosine, and least commonly as thymine, we calculated the A-to-G and G-to-A error rates at each site for each animal and averaged all three sites, since the rates at the different sites were not significantly different from each other, and they did not depend on the genotype of the samples (Table 2 and data not shown). We reasoned that each transcript read could have arisen from an A-to-G or G-to-A misread at any one of the five edited sites, meaning, in other words, that each transcript is separated from five other transcripts by a single base pair difference. By multiplying our calculated error rates by the frequencies of the occurrence of the five closely related transcripts and summing the five resulting values, we were able to estimate the proportion of the reads of a given transcript that were likely to have arisen due to misreads of other transcripts (Table 3). Our calculations indicated that the majority of transcript reads, in every instance, do not result from sequencing error, even in the cases of the rarest transcripts, which were seen at lower frequency than the most common false transcripts. In fact, our calculated estimates of the expected frequencies of occurrence of the most common false transcripts were consistent with what was seen experimentally (data not shown), suggesting that our calculated thresholds were reasonable. Thus, we considered all of the transcripts to have occurred at rates above our detection threshold, though some appear to be extremely rare.

![Figure 1. Schematic of the ultra HTS strategy used to measure RNA editing.](image)
Comparison of results obtained by LTS and HTS

In parallel with our ultra HTS experiment, we also measured 5-HT<sub>2C</sub> RNA editing by the most common LTS approach to provide a realistic comparison of findings (24). First, we compared both methods with respect to their ability to detect all 32 possible transcripts (Table 4). Not surprisingly, HTS was able to detect all transcripts in both Pet-1 wild-type and knockout mice, whereas LTS detected only 20 of 32 possible transcripts, with 12 of those 20 detected in only one or the other genotype. Our LTS results are consistent with many previous studies in being able to detect only a subset of all theoretically possible transcripts (15). Thus, HTS appears to be superior to LTS with respect to the ability to comprehensively detect all transcripts.

Comparison of the overall editing frequencies at each of the five sites indicates that HTS and LTS report similar editing frequencies (Figure 2). Two-way ANOVA analysis with Bonferroni post-tests to compare LTS and HTS results indicates that, where comparison is possible (with the more common transcripts), there are no significant differences in the estimates obtained by the two methods. Thus, we validated both the method and the subsequent filters applied to the data. Two-way ANOVA analysis indicates that genotype has no effect on editing frequency variation (HTS \(P\)-value = 0.4369; LTS \(P\)-value = 0.0812). Bonferroni post-tests to perform pairwise comparisons of genotype effect confirmed that there is no significant between-genotype difference in editing frequencies measured by the two methods (Figure 2A). Furthermore, two-way ANOVA analysis

### Table 1. Complete transcript reads

| Isoform | Transcript | Complete read |
|---------|------------|---------------|
| INI     | AAAAA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| INV     | AAAAG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| ISI     | AAAGA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| ISV     | AAAGG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| IDI     | AAGAA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| IDV     | AAGAG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| IGI     | AAGGA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| IGV     | AAGGG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| MNI     | AGAAA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| MNV     | AGAGA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| MSI     | AGAGA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| MSV     | AGAGG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| MDI     | AGGAA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| MDV     | AGGAG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| MGI     | AGGGA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| MGV     | AGGGG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VDI     | GGGAA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VGV     | GGGGG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VNI     | GAAA        | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VNIV    | GGAGA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VSI     | GGAGA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VSV     | GGAGG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VDI     | GAGAA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VGV     | GAGAG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VNI     | GAAAG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VNV     | GAGAG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VSI     | GAAGA      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |
| VSV     | GAAGG      | TAGCAATACGTATACTCCATTTAGCATACGATCCGGTGTC |

### Table 2. Estimate of A-to-G and G-to-A Error Rates (%)

| Site | WT1  | WT2  | WT3  | KO1  | KO2  | KO3  | AVG |
|------|------|------|------|------|------|------|-----|
| Site 1 TTGAGCATAGCCGGTT | 0.08 | 0.07 | 0.08 | 0.07 | 0.07 | 0.05 | 0.07 |
| Site 2 TTGAGCATAGCCGGTT | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 | 0.04 | 0.05 |
| Site 3 TTGAGCATAGCCGGTT | 0.04 | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 |
| Average A-to-G error rate |
| Site 1 TTGAGCATAGCCGGTT | 0.05 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 |
| Site 2 TTGAGCATAGCCGGTT | 0.06 | 0.05 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 |
| Site 3 TTGAGCATAGCCGGTT | 0.03 | 0.04 | 0.03 | 0.04 | 0.05 | 0.05 | 0.04 |

### Average G-to-A error rate

| Site | WT1  | WT2  | WT3  | KO1  | KO2  | KO3  | AVG |
|------|------|------|------|------|------|------|-----|
| Site 1 TTGAGCATAGCCGGTT | 0.05 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 |
| Site 2 TTGAGCATAGCCGGTT | 0.06 | 0.05 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 |
| Site 3 TTGAGCATAGCCGGTT | 0.03 | 0.04 | 0.03 | 0.04 | 0.05 | 0.05 | 0.04 |
comparing common transcripts detected in both genotypes with both methods shows no significant effect of genotype on common transcript frequency differences, and Bonferroni post-tests confirm no significant effect of genotype on transcript frequencies (Figure 2B). Additionally, we would point out that HTS produces transcript frequency estimates that range over approximately five orders of magnitude, in contrast to LTS, where the estimates range over one order of magnitude. Not surprisingly, in measuring the frequencies of rare transcripts, HTS is clearly superior to LTS (Figure 2C).

HTS allows statistical comparison between wildtype and knockout animals with all 23 rare transcripts in question. LTS, in contrast, does not detect any one of the 23 rare transcripts in both wild-type and knockout animals, making any statistical comparison for the rare transcripts impossible. Two-way ANOVA analysis of the HTS data shows no effect of genotype on transcript frequency (P = 0.9867), which is confirmed by Bonferroni post-tests.

Multiplexing HTS technology to simplify the measurement of 5-HT_{2C} RNA editing under different experimental conditions

Since lowering endogenous brain serotonin via a genetic strategy did not significantly alter 5-HT_{2C} RNA editing, we wondered if pharmacologic manipulations might alter 5-HT_{2C} RNA editing. Simultaneously, we optimized our experimental protocol to generate more sequence reads with a lower error rate and to further reduce the cost to measure editing in each sample. To optimize the number

| Isoform | Transcript | % Arising from error—Method 1 | % Arising from error—Method 2 |
|---------|------------|-------------------------------|-------------------------------|
| INI     | AAAA       | 0.19 ± 0.01                   | 0.06 ± 0.01                   |
| INV     | AAAAA      | 0.10 ± 0.01                   | 0.03 ± 0.01                   |
| ISI     | AAAGA      | 0.34 ± 0.05                   | 0.11 ± 0.02                   |
| ISV     | AAGAA      | 0.14 ± 0.02                   | 0.04 ± 0.01                   |
| IDI     | AGAAG      | 1.08 ± 0.33                   | 0.34 ± 0.05                   |
| IDV     | AAGAG      | 1.81 ± 0.83                   | 0.65 ± 0.08                   |
| IGI     | AGAGA      | 1.09 ± 0.55                   | 0.34 ± 0.05                   |
| IGV     | AGAGG      | 2.92 ± 0.92                   | 0.91 ± 0.13                   |
| MNI     | AGAAA      | 2.03 ± 0.82                   | 0.63 ± 0.09                   |
| MNV     | AGAAG      | 4.51 ± 1.08                   | 1.40 ± 0.20                   |
| MSI     | AGAGA      | 32.66 ± 9.96                  | 10.14 ± 1.48                  |
| MSV     | AGAGG      | 19.55 ± 9.48                  | 6.07 ± 0.89                   |
| MDI     | AGGAA      | 48.26 ± 16.30                 | 14.99 ± 2.19                  |
| MDV     | AGGAG      | 16.12 ± 9.47                  | 5.01 ± 0.73                   |
| MGI     | AGGGA      | 0.37 ± 0.24                   | 0.11 ± 0.02                   |
| MGV     | AGGGG      | 13.44 ± 12.88                 | 4.17 ± 0.61                   |
| VDI     | GAGAA      | 1.76 ± 0.50                   | 0.55 ± 0.08                   |
| VDV     | GAGAG      | 1.82 ± 0.58                   | 0.57 ± 0.08                   |
| VGI     | GAGGG      | 3.44 ± 1.18                   | 1.07 ± 0.16                   |
| VGV     | GGGGG      | 3.39 ± 0.53                   | 1.05 ± 0.15                   |
| VNI     | GGAAA      | 0.28 ± 0.02                   | 0.09 ± 0.01                   |
| VNV     | GGGAG      | 0.06 ± 0.01                   | 0.02 ± 0.01                   |
| VSI     | GGGAG      | 0.17 ± 0.01                   | 0.05 ± 0.01                   |
| VSV     | GGGAG      | 0.09 ± 0.01                   | 0.03 ± 0.01                   |
| VDI     | GAGAA      | 0.33 ± 0.07                   | 0.10 ± 0.01                   |
| VDV     | GAGAG      | 0.88 ± 0.14                   | 0.27 ± 0.04                   |
| VGI     | GAGGG      | 0.16 ± 0.03                   | 0.05 ± 0.01                   |
| VGV     | GGGGG      | 0.14 ± 0.05                   | 0.04 ± 0.01                   |
| VNI     | GGGAG      | 0.25 ± 0.03                   | 0.08 ± 0.01                   |
| VNV     | GGGAG      | 0.51 ± 0.09                   | 0.16 ± 0.02                   |
| VSI     | GGGAG      | 2.14 ± 0.32                   | 0.66 ± 0.10                   |
| VSV     | GGGAG      | 1.69 ± 0.44                   | 0.52 ± 0.08                   |
of sequence reads generated, we altered the forward primer to incorporate a sequence which allows us to use the Illumina-optimized sequencing primer. To further reduce costs, we incorporated a sample identification tag in the forward primer, using a different forward primer/identification tag for each sample. As a result, we were able to multiplex 26 samples in one lane, reducing the cost of processing one sample by approximately a factor of 26. It should be noted that this experimental design necessitates a longer read length (76 bp). With these modifications, we generated 71,187,995 reads after filtering (Figure 1). We also calculated new transcript frequency thresholds for the multiplexed sequencing protocol. Notably, these new thresholds were considerably lower than in the original protocol (none >15%, and all but two of the rest <5%).

We proceeded to examine the effect of a variety of chronic treatment regimens. These included chronic agonist [LSD, 0.25 mg/kg (31); DOI, 1 mg/kg (32); MK-212, 5 mg/kg (33)], inverse agonist [SB206553, 5 mg/kg (34,35)], antimanic [lithium 200 mg/kg (36,37); valproate, 300 mg/kg (36,38,39)], antipsychotic [clozapine, 10 mg/kg (40); olanzapine 5 mg/kg (41–43)] and antidepressant [fluoxetine, 10 mg/kg (41,44–46); amitriptyline, 10 mg/kg (47)]. First, we treated C57BL/6 mice daily with saline, fluoxetine, amitriptyline or olanzapine for a 28-day period, the rationale being that fluoxetine is a selective serotonin reuptake inhibitor (SSRI), which should raise endogenous brain serotonin levels, and amitriptyline is a tricyclic antidepressant which also inhibits serotonin reuptake. Olanzapine is an atypical antipsychotic drug, which is also a non-selective 5-HT2C antagonist that would be predicted to have no effect on 5-HT2C editing based on our aforementioned Pet-1 results. We proceeded to measure the editing frequency at the A, B, C, D and E sites in three brain regions: striatum, hippocampus and cortex. Antidepressant effects are thought to involve changes in hippocampal function, and a previous study has examined the effect of fluoxetine on cortical 5-HT2C RNA editing (21). We examined striatal editing because 5-HT2C receptors are known to be highly expressed in this region (28,48,49). Interestingly, we found that fluoxetine-treated mice exhibited an increase in A and B site editing relative to their saline-treated littermates, with no change in C, D or E site editing in striatum and hippocampus, but not...
cortex (Figure 3A-C). Chronic amitriptyline, on the other hand, led to an increase in A and B site editing only in hippocampus. Olanzapine had no significant effect on 5-HT2C editing.

To further characterize our results, we examined whether our overall editing frequencies calculated at each site were consistent with findings at the transcript level. We reasoned that an increase in A and B site editing should lead to a decrease in transcripts that are unmodified at both sites (AA***), with a concomitant increase in deaminated transcripts (AG***, GA***, and/or GG***). As seen in Figure 3A–C, while AA***
frequency decreases and GG*** increases as predicted, AG*** and GA*** remain unchanged. Thus, fluoxetine and amitriptyline increase the editing frequencies at the A and B sites by increasing the simultaneous editing of those two sites, most likely by regulating ADAR1 activity. Furthermore, the increase in A and B site editing resulted in significant changes at the transcript level in either two or three out of 32 transcripts after fluoxetine treatment (Striatum: AAAAAA-INI, Saline—7.85% > Fluoxetine—5.70%, P < 0.01; AAAAG-INV, Saline—8.83% > Fluoxetine—5.35%, P < 0.001; GGAAAG-VNV, SALINE—32.50% < Fluoxetine—35.42%, P < 0.001; Hippocampus: AAAAG-INV, Saline—17.84% > Fluoxetine—12.22%, P < 0.001; GGAAAG-VNV, Saline—27.17% < Fluoxetine—31.57%, P < 0.001) and four of 32 transcripts after amitriptyline treatment (Hippocampus: AAAAAA-INI, Saline—10.59% > Amitriptyline—6.94%, P < 0.05; AAAAG-INV, Saline—17.84% > Amitriptyline—8.36%, P < 0.001; GGAAG-VNV, Saline—27.17% < Amitriptyline—35.21%, P < 0.001; GGAAGG-VNV, Saline—13.59% < Amitriptyline—17.26%, P < 0.05). There were no significant changes in any of the other 28 transcripts after chronic fluoxetine or amitriptyline treatment, and no significant changes whatsoever after olanzapine treatment.

We next examined several other drugs which can directly (e.g. LSD, DOI, SB206553, MK-212, clozapine) or indirectly (e.g. lithium, valproate) modulate 5-HT2C signaling. The treatment regimens were 10-day saline, LSD and DOI; and 14-day saline, SB206553, MK-212, clozapine, lithium and valproate. SB206553, a relatively selective 5-HT2C inverse agonist, caused a small but significant increase in 5-HT2C editing at the A and B sites in striatum only (Figure 4A), decreasing the proportion of AA*** transcripts and increasing the proportion of GG*** transcripts as expected. Lithium, which does not act directly at 5-HT2C receptors, but which can alter 5-HT2C signaling (50), increased editing at the C and D sites, which are edited by ADAR2, in cortex only, resulting in the expected changes in the proportions of ***AA and ***GG transcripts (Figure 4B). LSD, DOI, MK-212, clozapine and valproate did not alter 5-HT2C editing in any of the brain regions examined (Table 5).

**DISCUSSION**

In this article, we developed and utilized an ultra HTS approach using the Illumina Genome Analyzer II platform to analyze 5-HT2C RNA editing and provide quantitative estimates of editing site frequencies and transcript/isoform frequencies. We also compared our ultra high-throughput approach to the most commonly used low-throughput approach and show that our high-throughput approach is superior in part because it detects all transcripts, facilitating between-genotype comparisons of even rare transcripts, which is either impossible or prohibitively expensive and laborious by the more common low-throughput approach. We then used our novel approach to assess the effect of endogenous serotonin on RNA editing of the 5-HT2C receptor by comparing RNA editing frequencies in the hippocampi of Pet-1 wild-type and knockout mice, which have a defective serotonin system due to dysfunctional serotonergic raphe neurons that produce almost no serotonin. Surprisingly, we found that abnormally low levels of brain serotonin had no significant effect on 5-HT2C receptor RNA editing. We also show that the editing frequencies at each of the five individual editing sites are unchanged and that there is little or no alteration in the frequency of any one of the 32 5-HT2C transcripts in the absence of a normally functioning central serotonin system. An examination of the effect on 5-HT2C editing of 10 different drugs with varying mechanisms of action indicated that their ability to modulate editing could not be predicted in a straightforward manner based on their activity at 5-HT2C receptors. Notably, our results in untreated mice are consistent with previous studies measuring the proportions of transcripts edited at the five edited sites (21,24).

Prior studies have yielded inconsistent results regarding the effects of various pharmacological manipulations of the serotonergic system on 5-HT2C RNA editing. As an example, one study reported increases in editing frequencies at the A, B, C and D sites after fluoxetine treatment of BALB/c mice, and no RNA editing changes after fluoxetine treatment in C57BL/6 mice (though there were consistent trends towards a decrease at the A, B, C and D sites). It should be noted that these mice were subjected to a modified forced swim test (FST) on their last 2 days of treatment (51). Another study in rats reported decreases in A, B and E site editing frequencies after fluoxetine treatment (52).

A potential shortcoming of all of these previous studies is the small number of sequences that was sampled, typically 50 or so samples per animal, with three or four animals in each treatment group. Small sample sizes are inevitable due to the labor-intensive nature of methods that rely on sequencing transcripts derived from individual bacterial clones (one clone = one transcript). The small sample sizes make measuring editing at the E site difficult because of the very low frequency of editing at this site (<5%). Not surprisingly, therefore, the most common change reported between treatment groups is at the E site, which is the most difficult to measure accurately. Furthermore, previous studies generally focus only on common transcripts, because rare transcripts are impossible to identify and quantify given the small sample sizes. Other studies rely on primer-extension analysis, which does not allow for the comprehensive assessment of individual transcript frequencies, but merely editing frequencies at each site. Two very recent articles apply next-generation sequencing technology to measuring or discovering RNA editing (53,54). Both sequenced only a few hundred to a few thousand 5-HT2C transcripts—an approach comparable to what can be done with presently established methods. In addition, neither study examined all 32 conceivable transcripts and no comparison was made with a gold standard method to validate the results.

Our novel HTS method has a number of advantages with respect to the previously established methods for quantifying RNA editing. First, HTS is many orders of
magnitude less expensive per sequence. Furthermore, the Genome Analyzer II, on which our HTS experiment was performed, is amenable to multiplexing 26 or more samples in each lane of a flow cell, which cuts the cost per experiment by an order of magnitude, making RNA editing analysis by HTS considerably less expensive on a per animal basis than RNA editing analysis by LTS.

Second, measuring RNA editing by HTS is less labor-intensive than LTS. For HTS, PCR fragments are simply generated and loaded into the Cluster Station and then the Genome Analyzer II, which sequences individual fragments directly. To generate similar information by LTS, fragments must be first ligated into a vector, the vector transformed into bacteria, the bacteria plated, individual bacterial clones picked and grown, plasmids

Table 5. Summary of findings from multiplexed experiment

| Drug       | Treatment length | Striatum | Hippocampus | Cortex |
|------------|------------------|----------|-------------|--------|
| Fluoxetine | 28 D             | *        | *           | NS     |
| Amitriptyline | 28 D         | NS       | NS          | NS     |
| Olanzapine | 28 D             | NS       | NS          | NS     |
| SB206553   | 14 D             | *        | NS          | NS     |
| Lithium    | 14 D             | NS       | NS          | *      |
| Clozapine  | 14 D             | NS       | NS          | NS     |
| MK-212     | 14 D             | NS       | NS          | NS     |
| Valproate  |                  |          |             |        |
| LSD        | 10 D             |          |             |        |
| DOI        | 10 D             |          |             |        |

*The treatment regimen significantly altered editing. NS, no significant effect of the treatment regimen on editing.
purified, and finally the inserted fragment sequenced by Sanger sequencing. Third, HTS is advantageous as compared to primer-extension analysis and other similar PCR-based strategies in that data is digital rather than analog, with at least some of the advantages associated with digital information (55). Fourth, HTS permits the analysis of rare transcripts, which is either impossible or prohibitively expensive and labor intensive by the LTS method. The analysis of rare transcripts is also impossible by analog methods such as primer-extension analysis. We have also compared our results, where possible, to gold standard LTS, thus validating our method and the sequence quality filters we used.

To our knowledge, this study represents the first comprehensive measurement of the frequencies of all 32 possible 5-HT_{2C} transcripts. Although we detected many rare transcripts, it is not clear to what extent rare transcripts may or may not be important in vivo. Experiments with mice expressing only the fully edited VGV isoform, however, have indicated that mutant VGV mice exhibit increases in total 5-HT_{2C} expression as compared to wild-type mice, along with dramatic reductions in fat mass despite hyperphagia (18). This suggests the possibility that alterations in rare transcript frequencies may have important physiological consequences.

Finally, we would like to note that our data are easily reconcilable with the known mechanisms by which the 5-HT_{2C} receptor pre-mRNA is edited by ADAR1, which edits the A and B sites, and ADAR2, which edits the C and D sites (16). Our data suggest that fluoxetine/amitriptyline and SB206553, which have the opposite effects on signaling through the 5-HT_{2C} receptor but nonetheless all increase editing frequency at the A and B sites in at least one brain region, modulate 5-HT_{2C} RNA editing by influencing ADAR1 function at the receptor without affecting function of ADAR2. In contrast, lithium appears to affect only the ability of ADAR2 to edit 5-HT_{2C} pre-mRNA. Furthermore, our data indicate that chronic treatment leads to reciprocal changes in transcripts that are either unedited or fully edited at the A and B or C and D sites, with no change in transcripts edited at only one or the other site. We also show region-specific changes with respect to the handful of drugs which do affect editing (fluoxetine, amitriptyline, SB206553 and lithium) Finally, although we report significant changes in editing after some drug regimens, most of these changes are relatively small in magnitude (typically <10%) and it is unclear if such small changes are physiologically significant.

In summary, we have developed and optimized a novel ultra high-throughput method for measuring RNA editing digitally by adapting newly developed genome-wide sequencing tools. Our method is inexpensive, technically feasible for most laboratories, and provides more comprehensive information regarding 5-HT_{2C} receptor editing than either existing analog methods or digital low-throughput methods. We applied our newly developed ultra high-throughput method to assess whether or not modulating endogenous brain serotonin would alter 5-HT_{2C} RNA editing. We demonstrated through our more powerful measurement method that lowering endogenous brain serotonin levels does not affect 5-HT_{2C} RNA editing in vivo. In contrast, treating mice with chronic fluoxetine, amitriptyline, SB206553 and lithium increased editing at a subset of the sites in one more brain regions, whereas chronic LSD, DOI, MK-212, valproate, clozapine and olanzapine had no effect. Our data suggest that the ability of a drug to alter 5-HT_{2C} RNA editing cannot be predicted from its activity at 5-HT_{2C} receptors. Given its considerable advantages, massively parallel HTS is likely to rapidly become the method of choice for quantifying RNA editing as next-generation sequencing platforms become more widely available.

ACKNOWLEDGEMENTS

We would like to thank Dr Evan Deneris for providing us with the Pet-1 knockout mice on which the studies were performed. We are also grateful to the UNC Genome Analysis Facility for performing the Sanger sequencing for the LTS experiments and the UNC High Throughput Sequencing Facility for their help in performing the HTS studies.

FUNDING

NIMH61887, U19MH82441; NIMH Psychoactive Drug Screening Program (to A.A., D.U., M.S.F., N.H.J., W.K.K., B.L.R.); NARSAD Distinguished Investigator (to B.L.R.); CWRU MSTP and National Institutes of Health (T32 GM007250 to A.A.); UNC Chapel Hill and the Lineberger Cancer Center. Funding for open access charge: National Institutes of Health (U19MH82441, RO1MH61887).

Conflict of interest statement. None declared.

REFERENCES

1. Benne, R., Van den Burg, J., Brakenhoff, J.P., Sloof, P., Van Boom, J.H. and Tromp, M.C. (1986) Major transcript of the frameshifted coxII gene from trypanosome mitochondria contains four nucleotides that are not encoded in the DNA. Cell, 46, 819–826.
2. Keegan, L.P., Gallo, A. and O’Connell, M.A. (2001) The many roles of an RNA editor. Nat. Rev. Genet., 2, 869–878.
3. Sommer, B., Kohler, M., Spengel, R. and Seeburg, P.H. (1991) RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell, 67, 11–19.
4. Bass, B.L. (2002) RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem., 71, 817–846.
5. Palladino, M.J., Keegan, L.P., O’Connell, M.A. and Reenan, R.A. (2000) A-to-I pre-mRNA editing in Drosophila is primarily involved in adult nervous system function and integrity. Cell, 102, 437–449.
6. Wang, Q., Khillan, J., Gadue, P. and Nishikura, K. (2000) Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science, 290, 1765–1768.
7. Higuchi, M., Maas, S., Single, F.N., Hartner, J., Rozov, A., Burnashev, N., Feldmeyer, D., Spengel, R. and Seeburg, P.H. (2000) Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature, 406, 78–81.
8. Paul,M.S. and Bass,B.L. (1998) Inosine exists in mRNA at tissue-specific levels and is most abundant in brain mRNA. EMBO J., 17, 1120–1127.

9. Athanasiadis,A., Rich,A. and Maas,S. (2004) Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol., 2, e391.

10. Blow,M., Futtrel,P.A., Wooster,R. and Stratton,M.R. (2004) A survey of RNA editing in human brain. Genome Res., 14, 2379–2387.

11. Kikuno,R., Nagase,T., Waki,M. and Ohara,O. (2002) HUGE: a database for human large proteins identified in the Kazusa cDNA sequencing project. Nucleic Acids Res., 30, 166–168.

12. Kim,D.D., Kim,T.T., Walsh,T., Kobayashi,Y., Matiss,T.C., Buysse,S. and Gabriel,A. (2004) Widespread RNA editing of embedded alu elements in the human transcriptome. Genome Res., 14, 1719–1725.

13. Levanon,E.Y., Eisenberg,E., Yelin,R., Nemzer,S., Hallegger,M., Shemes,R., Fligelman,Z.Y., Shoshan,A., Pollock,S.R., Szybule,D. et al. (2004) Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol., 22, 1001–1005.

14. Berg,K.A., Cropper,J.D., Niswender,C.M., Sanders-Bush,E., Hartner,J.C., Loiacono,R., Sexton,P.M. and Christopoulos,A. (2008) RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacol. Ther., 119, 7–23.

15. Athanasiadis,A., Rich,A. and Maas,S. (2004) Widespread A-to-I RNA editing of the serotonin 2C receptor: comparisons among inbred mouse strains. Gene, 382, 39–46.

16. Kodama,M., Fujioka,T. and Duman,R.S. (2004) Chronic antidepressant treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. J. Neurosci., 24, 6590–6599.

17. Molineaux,S.M., Jessell,T.M., Axel,R. and Julius,D. (1989) 5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. Proc. Natl Acad. Sci. USA, 86, 6793–6797.

18. Mukherjee,D.R., Balasubramanian,S., Swerdlow,H.P., Smith,G.P., Milton,J., Brown,C.G., Hall,K.P., Evers,D.J., Barnes,C.L., Bignell,H.R. et al. (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature, 456, 53–59.

19. Ruparel,H., Li,L., Li,Z., Bai,X., Kim,D.H., Turro,N.J. and Ju,J. (2005) Design and synthesis of a 3’-O-allyl photocleavable fluorescent nucleotide as a reversible terminator for DNA sequencing by synthesis. Proc. Natl Acad. Sci. USA, 102, 5932–5937.

20. Buckholtz,N.S., Freedman,D.X. and Middaugh,L.D. (1985) Daily LSD administration selectively decreases serotonin2 receptor binding in rat brain. Eur. J. Pharmacol., 109, 421–425.

21. Buckholtz,N.S., Zhou,D.F. and Freedman,D.X. (1988) Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors. Life Sci., 42, 2439–2445.

22. Cunningham,K.A., Callahan,P.M. and Appel,J.B. (1986) Discriminative stimuli properties of the serotonin agonist MK 212, Psychopharmacol., 90, 193–197.

23. Griebel,G., Perrault,D. and Sanger,D.J. (2004) RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. J. Neurosci., 28, 12834–12844.

24. Griebel,G., Perrault,D. and Sanger,D.J. (2004) RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. J. Neurosci., 28, 12834–12844.

25. Stockton,M.E. and Rasmussen,K. (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neurpsychopharmacol., 14, 97–105.

26. Malberg,J.E., Eisch,A.J., Nestler,E.J. and Duman,R.S. (2000) Chronic antidepressant treatment increases neurogenesis in adult hippocampus. J. Neurosci., 20, 10529–10532.

27. Griebel,G., Perrault,D. and Sanger,D.J. (2004) RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. J. Neurosci., 28, 12834–12844.

28. Molineaux,S.M., Jessell,T.M., Axel,R. and Julius,D. (1989) 5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. Proc. Natl Acad. Sci. USA, 86, 6793–6797.

29. Bentley,D.R., Balasubramanian,S., Swerdlow,H.P., Smith,G.P., Milton,J., Brown,C.G., Hall,K.P., Evers,D.J., Barnes,C.L., Bignell,H.R. et al. (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature, 456, 53–59.

30. Ruparel,H., Li,L., Li,Z., Bai,X., Kim,D.H., Turro,N.J. and Ju,J. (2005) Design and synthesis of a 3’-O-allyl photocleavable fluorescent nucleotide as a reversible terminator for DNA sequencing by synthesis. Proc. Natl Acad. Sci. USA, 102, 5932–5937.

31. Buckholtz,N.S., Freedman,D.X. and Middaugh,L.D. (1985) Daily LSD administration selectively decreases serotonin2 receptor binding in rat brain. Eur. J. Pharmacol., 109, 421–425.

32. Buckholtz,N.S., Zhou,D.F. and Freedman,D.X. (1988) Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors. Life Sci., 42, 2439–2445.

33. Paul,M.S. and Bass,B.L. (1998) Inosine exists in mRNA at tissue-specific levels and is most abundant in brain mRNA. EMBO J., 17, 1120–1127.

34. Athanasiadis,A., Rich,A. and Maas,S. (2004) Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol., 2, e391.

35. Blow,M., Futtrel,P.A., Wooster,R. and Stratton,M.R. (2004) A survey of RNA editing in human brain. Genome Res., 14, 2379–2387.

36. Kikuno,R., Nagase,T., Waki,M. and Ohara,O. (2002) HUGE: a database for human large proteins identified in the Kazusa cDNA sequencing project. Nucleic Acids Res., 30, 166–168.

37. Kim,D.D., Kim,T.T., Walsh,T., Kobayashi,Y., Matiss,T.C., Buysse,S. and Gabriel,A. (2004) Widespread RNA editing of embedded alu elements in the human transcriptome. Genome Res., 14, 1719–1725.

38. Levanon,E.Y., Eisenberg,E., Yelin,R., Nemzer,S., Hallegger,M., Shemes,R., Fligelman,Z.Y., Shoshan,A., Pollock,S.R., Szybule,D. et al. (2004) Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol., 22, 1001–1005.

39. Berg,K.A., Cropper,J.D., Niswender,C.M., Sanders-Bush,E., Hartner,J.C., Loiacono,R., Sexton,P.M. and Christopoulos,A. (2008) RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacol. Ther., 119, 7–23.

40. Athanasiadis,A., Rich,A. and Maas,S. (2004) Widespread A-to-I RNA editing of the serotonin 2C receptor: comparisons among inbred mouse strains. Gene, 382, 39–46.

41. Kodama,M., Fujioka,T. and Duman,R.S. (2004) Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiat., 56, 570–580.

42. Seeman,P., Weinsenker,D., Quirion,R., Srivastava,L.K., Bhadrwaj,S.K., Grandy,D.K., Premont,R.T., Sotnikova,T.D., Boks,P., El-Ghundi,M. et al. (2005) Dopamine supersensitivity correlates with D2H, dopamine, and Atypical antipsychotic drug actions at serotonin receptors. J. Neurosci., 29, 7124–7136.

43. Kodama,M., Fujioka,T. and Duman,R.S. (2004) Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiat., 56, 570–580.

44. Seeman,P., Weinsenker,D., Quirion,R., Srivastava,L.K., Bhadrwaj,S.K., Grandy,D.K., Premont,R.T., Sotnikova,T.D., Boks,P., El-Ghundi,M. et al. (2005) Dopamine supersensitivity correlates with D2H, dopamine, and Atypical antipsychotic drug actions at serotonin receptors. J. Neurosci., 29, 7124–7136.

45. Stockton,M.E. and Rasmussen,K. (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neurpsychopharmacol., 14, 97–105.

46. Malberg,J.E., Eisch,A.J., Nestler,E.J. and Duman,R.S. (2000) Chronic antidepressant treatment increases neurogenesis in adult hippocampus. J. Neurosci., 20, 9104–9110.

47. Santarrelli,L., Saxe,M., Gross,C., Surget,A., Battaglia,F., Dulawa,S., Weissbaum,N., Lee,J., Duman,R. and Arancio,O. et al. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 301, 805–809.
and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). *Proc. Natl Acad. Sci. USA*, 99, 3182–3187.

47. Heal, D.J., Hurst, E.M., Prow, M.R. and Buckett, W.R. (1990) An investigation of the role of 5-hydroxytryptamine in the attenuation of presynaptic alpha 2-adrenoceptor-mediated responses by antidepressant treatments. *Psychopharmacol.*, 101, 100–106.

48. Clemett, D.A., Punhani, T., Duxon, M.S., Blackburn, T.P. and Fone, K.C. (2000) Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. *Neuropharmacol.*, 39, 123–132.

49. Lopez-Gimenez, J.F., Tecott, L.H., Palacios, J.M., Mengod, G. and Vilaro, M.T. (2002) Serotonin 5-HT (2C) receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. *J. Neurosci. Res.*, 67, 69–85.

50. Basselin, M., Chang, L., Seemann, R., Bell, J.M. and Rapoport, S.I. (2003) Chronic lithium administration potentiates brain arachidonic acid signaling at rest and during cholinergic activation in awake rats. *J. Neurochem.*, 85, 1553–1562.

51. Englander, M.T., Dulawa, S.C., Bhansali, P. and Schmauss, C. (2005) How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. *J. Neurosci.*, 25, 648–651.

52. Iwamoto, K., Nakatani, N., Bundo, M., Yoshikawa, T. and Kato, T. (2005) Altered RNA editing of serotonin 2C receptor in a rat model of depression. *Neurosci Res.*, 53, 69–76.

53. Li, J.B., Levanon, E.Y., Yoon, J.K., Aach, J., Xie, B., Leproust, E., Zhang, K., Gao, Y. and Church, G.M. (2009) Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. *Science*, 324, 1210–1213.

54. Wahlstedt, H., Daniel, C., Enstroo, M. and Ohman, M. (2009) Large-scale mRNA sequencing determines global regulation of RNA editing during brain development. *Genome Res.*, 19, 978–986.

55. Audic, S. and Claverie, J.M. (1997) The significance of digital gene expression profiles. *Genome Res.*, 7, 986–995.